Pharma BD Deal Intelligence
BMS's $190M Kosan bet fizzled: lead Hsp90 candidate killed in Phase 3, and the epothilone asset (already approved pre-deal) was quietly offloaded to R-Pharm seven years later for a fraction of the purchase price.
Full analysis, sources & comparables →BMS announces $5.50/share cash tender ($190M net) to acquire Kosan, citing pipeline enhancement with Hsp90 inhibitors and epothilones.
Acquisition adds two anticancer compound classes to BMS pipeline; transaction expected to close third quarter 2008.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$5.50/share cash tender; Hsp90 inhibitors, epothilones; closed June 26 2008
BMS's $190M Kosan bet fizzled: lead Hsp90 candidate killed in Phase 3, and the epothilone asset (already approved pre-deal) was quietly offloaded to R-Pharm seven years later for a fraction of the purchase price.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Kosan Biosciences Incorporated (this deal) | 2008 | $190M | 22 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |